Abstract
RNA interference (RNAi) is a mechanism in which double-stranded (ds) RNA acts as a guide to sequence-specifically suppress gene expression. To achieve targeted knock-downs of gene function in mammalian cells, in vitro synthesised small interfering RNAs (siRNAs) can be introduced transiently into cells or, for more stable suppression by RNAi, various vector strategies can be employed to achieve prolonged in vivo synthesis of targeting RNA sequences. RNAi, beyond being a powerful experimental tool, has been widely promoted as a future gene-targeted therapeutic strategy of exquisite specificity. In the context of cancer, in which mutation, over-expression and de-novo acquisition of tumour-promoting genes are of central importance to the pathology, multiple molecular targets have been proposed for RNAi-based therapies. In this review, we will summarise what is known about the biology of RNAi in mammalian cells, outline the various expression and delivery strategies that have been developed, and discuss the features of possible therapeutic gene targets. We will also highlight the present technical limitations of RNAi that will need to be addressed if it is to be developed therapeutically, including the important issues of effective delivery and the potential for development of tumour resistance.
Keywords: cancer, rnai, rna interference, therapy, tumor
Current Cancer Therapy Reviews
Title: RNA Interference: A New Targeted Tumour Therapy?
Volume: 1 Issue: 1
Author(s): Jane M.E. Withey and Mark R. Crompton
Affiliation:
Keywords: cancer, rnai, rna interference, therapy, tumor
Abstract: RNA interference (RNAi) is a mechanism in which double-stranded (ds) RNA acts as a guide to sequence-specifically suppress gene expression. To achieve targeted knock-downs of gene function in mammalian cells, in vitro synthesised small interfering RNAs (siRNAs) can be introduced transiently into cells or, for more stable suppression by RNAi, various vector strategies can be employed to achieve prolonged in vivo synthesis of targeting RNA sequences. RNAi, beyond being a powerful experimental tool, has been widely promoted as a future gene-targeted therapeutic strategy of exquisite specificity. In the context of cancer, in which mutation, over-expression and de-novo acquisition of tumour-promoting genes are of central importance to the pathology, multiple molecular targets have been proposed for RNAi-based therapies. In this review, we will summarise what is known about the biology of RNAi in mammalian cells, outline the various expression and delivery strategies that have been developed, and discuss the features of possible therapeutic gene targets. We will also highlight the present technical limitations of RNAi that will need to be addressed if it is to be developed therapeutically, including the important issues of effective delivery and the potential for development of tumour resistance.
Export Options
About this article
Cite this article as:
Withey M.E. Jane and Crompton R. Mark, RNA Interference: A New Targeted Tumour Therapy?, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952447
DOI https://dx.doi.org/10.2174/1573394052952447 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
Current Pharmaceutical Design New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Cytisine - From the Past to the Future
Current Pharmaceutical Design Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets DNA Mismatch Repair Deficiency, Resistance to Cancer Chemotherapy and the Development of Hypersensitive Agents
Current Topics in Medicinal Chemistry Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews Exploring Confluence-Related Signalling to Modulate the Expression of Oct4 – A Role in Facilitating Mouse Somatic Cell Reprogramming?
Current Stem Cell Research & Therapy N-Hydroxyguanidines as Substrates of Nitric Oxide Synthases
Current Topics in Medicinal Chemistry Life and Death of Leukemic Cells Under Bcr-Abl Signaling Control
Current Cancer Therapy Reviews MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry Perspectives on Sesquiterpene Lactones in Inflammation and Cancer
Current Drug Targets Leptin, Ciliary Neurotrophic Factor, Leukemia Inhibitory Factor and Interleukin- 6: Class-I Cytokines Involved in the Neuroendocrine Regulation of the Reproductive Function
Current Protein & Peptide Science Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy